Edmolin.com

Informed Today Influential Tomorrow

Medicine

TLX Cargo Invents SOLARAP – European Pharmaceutical Manufacturer

UV radiation poses a significant threat to our skin, with melanin pigments providing partial protection by absorbing and reflecting incoming radiation. Drawing inspiration from this natural defence, TLX Cargo developed SOLARAP, the next generation solar barrier material used in TLX8 thermal pallet covers.

TLX8 is designed to protect both pharmaceutical and perishable shipments from extreme solar radiation on the tarmac and mitigate temperature excursions during transportation.

Thomas Hunt, CEO of TLX Cargo, shares, “After two years of dedicated research and development we have an exceptional thermal pallet cover to offer the market in 2024. Our team have come up with a new concept in solar barrier material that will be used to protect temperature sensitive shipments globally. SOLARAP nano-pores boast a remarkable surface area of 35.3 m2/g, equivalent to eight football pitches. These miniature circular pores form an effective barrier to ultraviolet by scattering and absorbing incoming radiation”.

Senior Scientist, Alice Harrop explains, “Protecting vaccines from shock temperature increases is challenging due to the diverse spectrum of solar radiation. These waves vary in intensity and angle of attack, influenced by atmospheric conditions and the sun’s position. SOLARAP adapts accordingly, working harder as temperatures rise”.

TLX8 is designed to protect both pharmaceutical and perishable shipments from extreme solar radiation on the tarmac and mitigate temperature excursions during transportation.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *

Medicine

GSK’s RSV Vaccine Accepted Under Priority Review in USGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population. Arexvy is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV. The application is supported by positive results from a phase III trial [NCT05590403]4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to underlying medical conditions. GSK used a Priority Review Voucher to reduce the US FDA review period of a supplemental Biologics License Application (sBLA) by four months. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is 7 June 2024. The burden of RSV disease in adults is likely to be underestimated due to lack of awareness, a lack of standardised testing, and under-detection in surveillance studies.5 People with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, chronic heart failure6 and diabetes,7 are at increased risk for RSV disease. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation, or death.8